Joanne Lord

Castillo-Riquelme M, Chalabi Z, Lord J, Guhl F, Campbell-Lendrum D, Davies C, Fox-Rushby J. (2008) Modelling geographic variation in the cost-effectiveness of control policies for infectious vector diseases: The example of Chagas disease.   Journal of Health Economics, vol 27, pp 405-26 doi: 10.1016/j.jhealeco.2007.04.005

 

Chalkidou K, Lord J, Fischer A, Littlejohns P (2008) Evidence-Based Decision Making: When Should We Wait For More Information? Health Affairs, vol 27 (6), pp 1642-53  doi:10.1377/hlthaff.27.6.1642

 

Latimer N, Lord J, Grant R et al (2009) Cost effectiveness of COX 2 selective inhibitors and traditional NSAIDs alone or in combination with a proton pump inhibitor for people with osteoarthritis, BMJ, vol 339, b2538 doi: 10.1136/bmj.b2538

 

Brunetti M, Ruiz F, Lord J et al (2010) Grading economic evidence, Editors: Shemilt I, Mugford M, Vale L, Donaldson C, and Marsh K. Evidence-based Decisions and Economics: Health Care, Social Welfare, Education and Criminal Justice, vol 10, pp 114-33. Oxford, John Wiley, doi: 10.1002/9781444320398

 

Latimer N, Lord J, Grant R, O’Mahony R, Dickson J, Conaghan PG (forthcoming) Value of Information in the Osteoarthritis Setting: Cost Effectiveness of COX-2 Selective Inhibitors, Traditional NSAIDs and Proton Pump Inhibitors, Pharmacoeconomics